List of Excipients in Branded Drug BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pacific Pharma Inc	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	brimonidine tartrate, timolol maleate	82182-455	BENZALKONIUM CHLORIDE
Pacific Pharma Inc	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	brimonidine tartrate, timolol maleate	82182-455	HYDROCHLORIC ACID
Pacific Pharma Inc	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	brimonidine tartrate, timolol maleate	82182-455	SODIUM HYDROXIDE
Pacific Pharma Inc	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE	brimonidine tartrate, timolol maleate	82182-455	SODIUM PHOSPHATE, DIBASIC

Generic Drugs Containing BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

Company	Ingredient	NDC	Excipient
Sandoz Inc	brimonidine tartrate and timolol maleate	0781-7186	BENZALKONIUM CHLORIDE
Sandoz Inc	brimonidine tartrate and timolol maleate	0781-7186	HYDROCHLORIC ACID
Sandoz Inc	brimonidine tartrate and timolol maleate	0781-7186	SODIUM HYDROXIDE
Sandoz Inc	brimonidine tartrate and timolol maleate	0781-7186	SODIUM PHOSPHATE, DIBASIC

What are the Most Frequently-Used Excipients in BRIMONIDINE TARTRATE AND TIMOLOL MALEATE?

# Of NDCs	Excipient
8	BENZALKONIUM CHLORIDE
8	HYDROCHLORIC ACID
8	SODIUM HYDROXIDE
2	SODIUM PHOSPHATE

Last updated: August 12, 2026

Brimonidine tartrate/timolol maleate is a mature fixed-dose ophthalmic combination with limited molecule-level exclusivity but meaningful commercial opportunity in preservative-free delivery, ocular-surface tolerability, unit-dose packaging, manufacturing efficiency, and regional generic supply. The main product, Combigan, combines an alpha-2 adrenergic agonist with a nonselective beta blocker for elevated intraocular pressure in glaucoma and ocular hypertension. Excipient selection affects stability, preservative exposure, comfort, container compatibility, patentability, and the ability to obtain approval through an ANDA or 505(b)(2) pathway.

Brimonidine Tartrate and Timolol Maleate Excipient Strategy and Commercial Opportunities

What is the commercial product and how does the combination work?

Brimonidine tartrate/timolol maleate ophthalmic solution is generally supplied at brimonidine tartrate 0.2% and timolol maleate 0.5%. The combination lowers intraocular pressure through two complementary mechanisms:

• Brimonidine reduces aqueous humor production and increases uveoscleral outflow.
• Timolol reduces aqueous humor production through beta-adrenergic blockade.

The FDA-approved branded product, Combigan, is indicated for patients with glaucoma or ocular hypertension who require adjunctive or combination therapy to control intraocular pressure. The labeled dose is one drop in the affected eye or eyes twice daily, approximately 12 hours apart [1].

Product attribute	Typical specification
Active ingredient 1	Brimonidine tartrate equivalent to brimonidine 0.2%
Active ingredient 2	Timolol maleate equivalent to timolol 0.5%
Dosage form	Sterile ophthalmic solution
Administration	Topical ocular
Typical dosing	One drop twice daily
Primary indications	Open-angle glaucoma and ocular hypertension
Reference product	Combigan
Product type	Small-molecule fixed-dose combination
Biosimilar pathway	Not applicable

The two-drug combination is commercially relevant because it replaces separate brimonidine and timolol bottles with one product. That can reduce administration complexity and may improve persistence, although the combination also exposes patients to the adverse-effect profiles of both actives.

What excipients are used in brimonidine/timolol ophthalmic solution?

The Combigan labeling identifies a conventional aqueous excipient system consisting of phosphate buffers, sodium chloride, benzalkonium chloride, purified water, and pH-adjusting agents. The labeled pH is approximately 6.5 [1].

Excipient category	Representative ingredient in the reference formulation	Commercial function
Preservative	Benzalkonium chloride, commonly 0.005%	Controls microbial growth in multidose packaging
Buffer	Sodium phosphate monobasic and sodium phosphate dibasic	Maintains pH during shelf life and use
Tonicity agent	Sodium chloride	Adjusts osmolality toward ocular tolerability
Vehicle	Purified water	Dissolves active ingredients and excipients
pH adjusters	Hydrochloric acid and/or sodium hydroxide	Sets the target pH
Container system	Sterile multidose ophthalmic bottle	Delivers repeated doses and limits contamination

The excipient system must satisfy four constraints simultaneously:

1. Maintain chemical stability of both active ingredients.
2. Preserve sterility throughout the in-use period.
3. Avoid precipitation, haze, crystallization, or adsorption.
4. Deliver a reproducible drop volume without excessive ocular irritation.

The principal formulation challenge is that brimonidine and timolol have different ionization, solubility, and stability characteristics. A buffer and pH that improve one active can alter the solubility or degradation pathway of the other. The formulation therefore requires dual-active compatibility studies rather than separate optimization of each ingredient.

How should the excipient strategy be optimized?

A commercial development program should treat the formulation as a combined stability and tolerability problem. The strongest opportunity is not simply replacing one inactive ingredient. It is developing a system that reduces preservative burden while preserving sterility, dose uniformity, and shelf life.

Preservative strategy

Benzalkonium chloride is effective, inexpensive, and familiar to regulators. It also creates a differentiation problem. Repeated exposure to benzalkonium chloride has been associated with ocular-surface irritation, tear-film disruption, and adverse effects in patients receiving chronic topical treatment [2].

Potential strategies include:

• Lower benzalkonium chloride concentration, if antimicrobial effectiveness remains adequate.
• Preservative-free unit-dose containers.
• Preservative-free multidose systems using one-way valves or specialized closure technology.
• Alternative preservatives, subject to ophthalmic safety and compatibility requirements.
• Reduced in-use exposure through smaller bottle sizes and shorter labeled in-use periods.

A preservative-free product has the clearest commercial rationale for patients with ocular-surface disease, dry eye, chronic glaucoma treatment, contact-lens intolerance, or high cumulative exposure to preserved ophthalmic products. It also creates a potential 505(b)(2) opportunity if the product differs materially from the reference product in preservative system, delivery technology, or packaging.

Buffer and pH strategy

Phosphate buffering is conventional, but it is not the only approach. Candidate systems may include citrate, borate, or low-capacity mixed buffers. A lower buffer capacity can improve comfort and allow the formulation to respond more naturally to the tear film. A higher buffer capacity can improve pH stability but may increase the sensory burden or complicate compatibility.

Development targets should include:

• pH near the tolerability and solubility optimum for both actives.
• Adequate buffer capacity without excessive phosphate concentration.
• No precipitation after dilution by tears.
• No visible particles after freeze-thaw or accelerated storage.
• Stable assay and impurity profile through expiry.
• Controlled osmolality, ideally within a range compatible with ocular comfort.

Phosphate-containing products also require careful assessment of interaction with container materials and the risk of precipitation under stressed conditions. The risk is usually manageable in a clear solution, but it must be evaluated across the full manufacturing and distribution profile.

Tonicity strategy

Sodium chloride is a standard tonicity agent. Alternatives or partial substitutes may include glycerin, mannitol, or other pharmaceutically accepted tonicity modifiers. These alternatives can change viscosity, drop size, comfort, and preservative performance.

A differentiated formulation should avoid unnecessary viscosity increases. A thicker solution may extend ocular residence time, but it can cause blurred vision, alter drop delivery, and increase patient rejection. For a twice-daily glaucoma product, comfort and consistent drop formation are generally more commercially valuable than maximum viscosity.

Chelating and antioxidant strategy

A chelator such as disodium edetate may improve preservative performance or reduce trace-metal catalyzed degradation. Its use must be justified because it can affect container compatibility and may change the formulation's regulatory profile.

Antioxidants may be considered if degradation pathways support their use. They should not be added solely to increase excipient complexity. Any antioxidant must be evaluated for ocular tolerability, extractables and leachables, and potential interaction with the active ingredients.

What formulations are protected by the strongest commercial strategy?

The most defensible formulation opportunities are those that combine a measurable patient or manufacturing benefit with a claimable technical distinction.

Formulation opportunity	Patient or business benefit	Likely IP focus
Preservative-free unit dose	Lower chronic preservative exposure	Composition, packaging, use method
Preservative-free multidose	Convenience with reduced preservative burden	Container-closure system and dosing method
Low-BAK formulation	Lower exposure while retaining multidose convenience	Preservative concentration and stability
Improved pH and osmolality	Better comfort and tolerability	Composition and therapeutic use
Reduced drop volume	Lower drug waste and systemic exposure	Delivery device and method of administration
Enhanced bottle ergonomics	Better adherence and administration accuracy	Device and packaging claims
Extended in-use stability	Lower waste and improved convenience	Formulation and container system
Low-volume unit dose	Better portability and reduced contamination risk	Package configuration and manufacturing

Composition claims are strongest when the excipient ranges are narrow and linked to an unexpected result, such as improved stability at lower preservative concentration or reduced ocular irritation without loss of antimicrobial protection.

Packaging claims can be valuable but are vulnerable to design-arounds. A patent covering a particular valve, bottle geometry, or drop-control structure may not block a competing container using a different mechanism.

When does brimonidine/timolol lose exclusivity?

The active ingredients are long-established small molecules. The main commercial reference product has already moved beyond its primary product exclusivity period, and generic versions of brimonidine/timolol ophthalmic solution have entered the U.S. market. The practical exclusivity analysis therefore centers on formulation, device, regulatory, and market-access barriers rather than basic composition-of-matter protection.

Exclusivity layer	Relevance to brimonidine/timolol
Composition-of-matter patents	Generally exhausted or commercially immaterial for these mature actives
New-drug exclusivity	Expired for the original combination product
Orange Book patents	Must be assessed for active, enforceable listings tied to the reference product
Formulation patents	Potentially relevant for preservative-free, low-BAK, stability, or pH systems
Device patents	Potentially relevant for multidose preservative-free delivery
Method-of-use patents	Narrower opportunity because the disease and combination use are established
ANDA pathway	Primary route for therapeutically equivalent generic products
505(b)(2) pathway	Relevant for material formulation, delivery, or packaging differences
Biosimilar pathway	Not relevant because the product is a small-molecule drug

FDA Orange Book listings are the controlling source for patent certifications and reference-product patent status. A commercial diligence review should distinguish listed patents from enforceable blocking rights, because listing status, expiration, terminal disclaimers, pediatric extensions, litigation, and settlement terms can affect launch timing differently [3].

What is the Orange Book status and Paragraph IV risk?

Generic applicants seeking approval of brimonidine/timolol ophthalmic solution generally use the ANDA pathway and must address applicable reference-product patents through certification or statement procedures. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed.

The main Paragraph IV risk categories are:

• Formulation patents covering the active solution and excipient ranges.
• Stability patents covering impurity control or shelf life.
• Container patents covering multidose delivery.
• Method-of-use patents covering patient populations or dosing schedules.
• Manufacturing patents covering sterile filling or active dissolution.

For a mature combination product, Paragraph IV risk is usually highest where a listed patent has a late expiration date and the generic product can challenge it without changing the clinical label. Risk is lower where the patent covers a narrow excipient combination that the generic can avoid through a different formulation.

A potential first-filer can obtain commercial leverage through 180-day exclusivity if it satisfies the statutory requirements. The value of that position depends on the number of approved or pending ANDAs, the strength of the reference patent estate, and the ability to maintain supply through launch.

Which companies are competing in brimonidine/timolol generics?

The U.S. market has included the branded reference product and multiple generic suppliers. Generic ophthalmic competition typically comes from companies with sterile ophthalmic manufacturing capacity, including large generic manufacturers and specialized ophthalmic producers. The competitive set can change as ANDAs are approved, discontinued, or placed on shortage status.

Commercial competition is determined by more than approval count. Key factors include:

• FDA-approved manufacturing sites.
• Inspection history and supply continuity.
• Ability to produce low-volume sterile batches economically.
• Access to ophthalmic-grade containers and closures.
• Wholesale contracting.
• Reimbursement and formulary placement.
• Ability to support multiple bottle sizes.
• Product availability during market shortages.

A supplier with a preservative-free or improved-tolerability formulation can compete against conventional generics even when it cannot match their lowest acquisition cost.

What manufacturing and IP barriers affect market entry?

The principal manufacturing barrier is sterile ophthalmic production. The product requires validated compounding, sterile filtration or aseptic processing, container-closure integrity, particulate control, and reliable fill-volume performance.

Key technical risks include:

• Incomplete dissolution of either active ingredient.
• pH drift during storage.
• Preservative adsorption to the container or closure.
• Active loss through surface adsorption.
• Incompatibility with elastomers or plastic components.
• Elevated degradation under heat and light.
• Drop-size variability caused by bottle geometry or viscosity.
• Microbial contamination during repeated use.

Manufacturing patents can protect a process if it produces a meaningful quality advantage, such as lower impurity levels or improved active recovery. Process patents alone rarely prevent entry if a competitor can achieve the same quality profile through a different process.

The better strategy is often a layered portfolio:

1. Composition claims covering the excipient ranges.
2. Stability claims covering impurity limits and shelf life.
3. Container-closure claims covering preservative-free delivery.
4. Method claims covering dosing or patient selection.
5. Manufacturing claims covering sterile preparation and filling.

How does brimonidine/timolol compare with separate-branded and competing glaucoma products?

The fixed-dose product competes with separate brimonidine and timolol bottles, other fixed-dose combinations, prostaglandin analogs, carbonic anhydrase inhibitors, and additional beta-blocker combinations.

Product type	Main advantage	Main limitation
Brimonidine/timolol fixed dose	Fewer bottles and fewer administration events	Preserved products may increase ocular-surface burden
Separate brimonidine plus timolol	Flexible titration and ingredient selection	More bottles and lower convenience
Prostaglandin analog monotherapy	Often once-daily dosing	Cosmetic and ocular-surface adverse effects
Dorzolamide/timolol	Established fixed-dose alternative	Different tolerability and dosing considerations
Brinzolamide/brimonidine	Non-beta-blocker combination option	Higher formulation complexity and different tolerability
Preservative-free alternatives	Reduced preservative exposure	Higher packaging and manufacturing cost

The commercial opportunity is strongest in segments where patients need combination therapy but experience discomfort, poor adherence, or dissatisfaction with conventional preserved multidose bottles.

What regulatory pathways support new commercial products?

ANDA pathway

An ANDA is appropriate for a product that demonstrates pharmaceutical equivalence and bioequivalence to the reference product and uses the same active ingredients, dosage form, strength, route, and conditions of use. Ophthalmic products require detailed evidence on sterility, particulate matter, preservative effectiveness where applicable, container closure, and product quality.

505(b)(2) pathway

A 505(b)(2) application may be appropriate for:

• Preservative-free reformulation.
• New multidose delivery system.
• Different excipient system.
• Different bottle or unit-dose presentation.
• Modified dosing schedule.
• Clinically meaningful tolerability differentiation.

The pathway may support three forms of commercial differentiation: regulatory exclusivity, formulation patenting, and premium pricing. It also carries greater development cost than a conventional ANDA because the sponsor must support the change from the reference formulation.

International opportunities

Outside the United States, opportunities depend on local registration requirements, reference-product status, and price controls. Preservative-free ophthalmic products may have particular commercial value in markets with high chronic glaucoma prevalence, strong ophthalmology specialist networks, or growing demand for ocular-surface-friendly products.

Regional opportunities may include:

• Unit-dose products for hospital and specialist channels.
• Affordable generic multidose bottles in price-sensitive markets.
• Premium preservative-free products in Western European and high-income Asian markets.
• Contract manufacturing for markets lacking local sterile ophthalmic capacity.

Geographic patent protection is likely to be more relevant for new formulation and device inventions than for the underlying active ingredients. Patent families should be evaluated separately in the United States, Europe, Japan, China, South Korea, Canada, Australia, and major Latin American markets.

What revenue exposure and launch scenarios exist?

The reference product faces conventional generic price erosion, but demand is supported by chronic treatment and combination-therapy use. Commercial scenarios include:

Scenario	Product profile	Market position
Lowest-cost generic	Conventional preserved multidose solution	High volume, low margin
Reliable second-source generic	Equivalent preserved product with strong supply	Contract and pharmacy channel
Low-BAK product	Reduced preservative concentration	Moderate premium potential
Preservative-free unit dose	Single-use packaging	Specialist and ocular-surface segment
Preservative-free multidose	Advanced container technology	Highest differentiation, higher COGS
505(b)(2) product	New formulation or administration system	Potential exclusivity and premium pricing

Revenue exposure should be assessed by product channel rather than total glaucoma-market size. The key metrics are annual prescription volume, payer mix, average selling price, generic substitution, bottle size, refill persistence, and the share of patients with ocular-surface disease.

A premium product must demonstrate one of three outcomes: better tolerability, improved adherence, or lower total treatment burden. Without measurable differentiation, the product is likely to compete primarily on price against established generics.

How strong is the patent estate for new brimonidine/timolol formulations?

The patent estate for the mature active combination is generally weaker than the patent estate for a new chemical entity. Stronger protection is possible when the invention links a narrow excipient system to a demonstrated technical effect.

The strongest claim concepts are likely to cover:

• Specific preservative concentrations below conventional levels.
• Preservative-free multidose systems with validated antimicrobial protection.
• Defined pH and buffer-capacity ranges.
• Specific osmolality windows linked to comfort or stability.
• Container materials that reduce adsorption or leachables.
• Drop-volume control mechanisms.
• Extended in-use stability.
• Manufacturing processes that reduce degradation products.

Method-of-use claims are more difficult to sustain when they merely recite treatment of glaucoma with known doses. They become more valuable when tied to a defined patient population, preservative intolerance, ocular-surface disease, or a clinically demonstrated dosing advantage.

Key Takeaways

• Brimonidine tartrate/timolol maleate is a mature small-molecule combination with generic competition and no biosimilar pathway.
• The reference formulation uses phosphate buffers, sodium chloride, purified water, pH adjusters, and benzalkonium chloride preservative [1].
• The clearest commercial opportunity is a preservative-free or low-preservative product with credible ocular-surface benefits.
• Preservative-free multidose delivery offers greater differentiation than a simple excipient substitution but requires stronger container and antimicrobial-control technology.
• ANDA is the main route for conventional generics; 505(b)(2) is more suitable for material formulation, packaging, or dosing changes.
• Patent value is likely to reside in formulation, device, stability, and manufacturing claims rather than active-ingredient patents.
• Sterile ophthalmic manufacturing, container compatibility, drop-volume control, and supply reliability are major entry barriers.
• Premium pricing requires evidence of improved tolerability, adherence, convenience, or reduced treatment burden.
• Orange Book patents, Paragraph IV certifications, litigation, and settlement terms determine the practical U.S. launch risk [3].

FAQs About Brimonidine Tartrate and Timolol Maleate Excipients

Is benzalkonium chloride necessary in brimonidine/timolol eye drops?

No. It is useful in conventional multidose packaging, but preservative-free unit-dose and engineered multidose systems can eliminate or reduce benzalkonium chloride exposure.

Can brimonidine/timolol be formulated as an ophthalmic suspension?

Yes, but a suspension would introduce additional risks involving particle size, redispersibility, dose uniformity, sedimentation, and patient comfort. A clear solution is generally more commercially straightforward.

Does a preservative-free version require a new clinical trial?

Not necessarily. The regulatory package depends on the extent of the formulation and delivery change. An ANDA may be possible for a therapeutically equivalent product, while a material reformulation may require a 505(b)(2) application and additional clinical or human-factor evidence.

Which excipient is most likely to create stability problems?

The main risk is usually the combined interaction among pH, buffer capacity, container materials, oxygen exposure, and trace metals rather than one isolated excipient. Both actives must be evaluated together through long-term and accelerated stability studies.

Can a new brimonidine/timolol formulation obtain market exclusivity?

Potentially. A qualifying 505(b)(2) product may obtain regulatory exclusivity, and a novel formulation or delivery system may support patents. Exclusivity depends on the approved indication, the nature of the clinical investigation, and the scope and validity of the patent claims.

References

1. U.S. Food and Drug Administration. (2023). Combigan (brimonidine tartrate and timolol maleate ophthalmic solution) prescribing information. AbbVie Inc.

2. European Medicines Agency. (2019). Benzalkonium chloride used as an excipient: Updated assessment report. European Medicines Agency.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2022). Guidance for industry: ANDAs for certain highly purified synthetic peptides. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Guidance for industry: Ophthalmic drug products, quality considerations. U.S. Department of Health and Human Services.